Advances in pediatric hematopoietic stem cell transplantation
Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has become a therapeutic option for an increasing number of patients with otherwise incurable leukemias, solid tumors, immunodeficiencies, hemoglobinopathies and metabolic diseases. For patients requiring an allogeneic transpla...
Gespeichert in:
| Veröffentlicht in: | Cancer biology & therapy 2008-10, Vol.7 (10), p.1533-1539 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1539 |
|---|---|
| container_issue | 10 |
| container_start_page | 1533 |
| container_title | Cancer biology & therapy |
| container_volume | 7 |
| creator | Barfield, Raymond Carlton Kasow, Kimberly Anne Hale, Gregory Alan |
| description | Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has become a therapeutic option for an increasing number of patients with otherwise incurable leukemias, solid tumors, immunodeficiencies, hemoglobinopathies and metabolic diseases. For patients requiring an allogeneic transplant, the addition of unrelated cord blood units and partially matched family member donors as alternate stem cell sources has increased the chances that an appropriate donor can be identified1,2. In addition, new approaches to stem cell graft engineering are yielding insights into potential cellular immune therapies, which may decrease the adverse effects of HSCT such as graft-versus-host disease (GVHD) and harness the alloimmune graft-versus-leukemia effect. Novel conditioning regimens, primarily reduced intensity and non-myeloablative regimens, allow patients with significant co-morbidities to undergo transplantation with reduced morbidity and mortality. Combinations of immune-modulatory cytokines and monoclonal antibodies with autologous and allogeneic transplantation are among the advances being explored in contemporary HSCT. |
| doi_str_mv | 10.4161/cbt.7.10.7046 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_18927494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69743441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-8e2e14846815ea48ddfd0d16322ce1caf42a8095e1d895b11749c33907994c9c3</originalsourceid><addsrcrecordid>eNptkD1PwzAURS0EoqUwsqJMbCl24sT2wFBVfEmVWGC2XPtFGCVxsF1Q_z2OUmBh8nvSeddXB6FLgpeU1ORGb-OSLdPGMK2P0JxUVZXzitXH41zynGLKZugshHeMC1bU4hTNCBcFo4LO0e3KfKpeQ8hsnw1grIre6uwNOhXd4CzEtIUIXaahbbPoVR-GVvVRRev6c3TSqDbAxeFdoNf7u5f1Y755fnharza5pgWOOYcCCOW05qQCRbkxjcGG1GVRaCBaNbRQHIsKiOGi2hKSuumyFJgJQXUaF-h6yh28-9hBiLKzYSykenC7IGvBaEkpSWA-gdq7EDw0cvC2U34vCZajL5l8STZuo6_EXx2Cd9sOzB99EJQAPAHpKwNha13QFpKwX3QMVD5pauEnk08ntm-c79SX862RUe1b55vkT9sgy__rfAN-ZIta</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69743441</pqid></control><display><type>article</type><title>Advances in pediatric hematopoietic stem cell transplantation</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Barfield, Raymond Carlton ; Kasow, Kimberly Anne ; Hale, Gregory Alan</creator><creatorcontrib>Barfield, Raymond Carlton ; Kasow, Kimberly Anne ; Hale, Gregory Alan</creatorcontrib><description>Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has become a therapeutic option for an increasing number of patients with otherwise incurable leukemias, solid tumors, immunodeficiencies, hemoglobinopathies and metabolic diseases. For patients requiring an allogeneic transplant, the addition of unrelated cord blood units and partially matched family member donors as alternate stem cell sources has increased the chances that an appropriate donor can be identified1,2. In addition, new approaches to stem cell graft engineering are yielding insights into potential cellular immune therapies, which may decrease the adverse effects of HSCT such as graft-versus-host disease (GVHD) and harness the alloimmune graft-versus-leukemia effect. Novel conditioning regimens, primarily reduced intensity and non-myeloablative regimens, allow patients with significant co-morbidities to undergo transplantation with reduced morbidity and mortality. Combinations of immune-modulatory cytokines and monoclonal antibodies with autologous and allogeneic transplantation are among the advances being explored in contemporary HSCT.</description><identifier>ISSN: 1538-4047</identifier><identifier>EISSN: 1555-8576</identifier><identifier>DOI: 10.4161/cbt.7.10.7046</identifier><identifier>PMID: 18927494</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Binding ; Biology ; Bioscience ; Calcium ; Cancer ; Cell ; Child ; Cycle ; Graft vs Host Disease - etiology ; Graft vs Host Disease - therapy ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cell Transplantation - trends ; Humans ; Immunologic Deficiency Syndromes - therapy ; Immunotherapy - methods ; Landes ; Leukemia - therapy ; Medical Oncology - methods ; Metabolism, Inborn Errors - therapy ; Organogenesis ; Osteopetrosis - therapy ; Proteins</subject><ispartof>Cancer biology & therapy, 2008-10, Vol.7 (10), p.1533-1539</ispartof><rights>Copyright © 2008 Landes Bioscience 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-8e2e14846815ea48ddfd0d16322ce1caf42a8095e1d895b11749c33907994c9c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18927494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barfield, Raymond Carlton</creatorcontrib><creatorcontrib>Kasow, Kimberly Anne</creatorcontrib><creatorcontrib>Hale, Gregory Alan</creatorcontrib><title>Advances in pediatric hematopoietic stem cell transplantation</title><title>Cancer biology & therapy</title><addtitle>Cancer Biol Ther</addtitle><description>Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has become a therapeutic option for an increasing number of patients with otherwise incurable leukemias, solid tumors, immunodeficiencies, hemoglobinopathies and metabolic diseases. For patients requiring an allogeneic transplant, the addition of unrelated cord blood units and partially matched family member donors as alternate stem cell sources has increased the chances that an appropriate donor can be identified1,2. In addition, new approaches to stem cell graft engineering are yielding insights into potential cellular immune therapies, which may decrease the adverse effects of HSCT such as graft-versus-host disease (GVHD) and harness the alloimmune graft-versus-leukemia effect. Novel conditioning regimens, primarily reduced intensity and non-myeloablative regimens, allow patients with significant co-morbidities to undergo transplantation with reduced morbidity and mortality. Combinations of immune-modulatory cytokines and monoclonal antibodies with autologous and allogeneic transplantation are among the advances being explored in contemporary HSCT.</description><subject>Binding</subject><subject>Biology</subject><subject>Bioscience</subject><subject>Calcium</subject><subject>Cancer</subject><subject>Cell</subject><subject>Child</subject><subject>Cycle</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - therapy</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cell Transplantation - trends</subject><subject>Humans</subject><subject>Immunologic Deficiency Syndromes - therapy</subject><subject>Immunotherapy - methods</subject><subject>Landes</subject><subject>Leukemia - therapy</subject><subject>Medical Oncology - methods</subject><subject>Metabolism, Inborn Errors - therapy</subject><subject>Organogenesis</subject><subject>Osteopetrosis - therapy</subject><subject>Proteins</subject><issn>1538-4047</issn><issn>1555-8576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkD1PwzAURS0EoqUwsqJMbCl24sT2wFBVfEmVWGC2XPtFGCVxsF1Q_z2OUmBh8nvSeddXB6FLgpeU1ORGb-OSLdPGMK2P0JxUVZXzitXH41zynGLKZugshHeMC1bU4hTNCBcFo4LO0e3KfKpeQ8hsnw1grIre6uwNOhXd4CzEtIUIXaahbbPoVR-GVvVRRev6c3TSqDbAxeFdoNf7u5f1Y755fnharza5pgWOOYcCCOW05qQCRbkxjcGG1GVRaCBaNbRQHIsKiOGi2hKSuumyFJgJQXUaF-h6yh28-9hBiLKzYSykenC7IGvBaEkpSWA-gdq7EDw0cvC2U34vCZajL5l8STZuo6_EXx2Cd9sOzB99EJQAPAHpKwNha13QFpKwX3QMVD5pauEnk08ntm-c79SX862RUe1b55vkT9sgy__rfAN-ZIta</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>Barfield, Raymond Carlton</creator><creator>Kasow, Kimberly Anne</creator><creator>Hale, Gregory Alan</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081001</creationdate><title>Advances in pediatric hematopoietic stem cell transplantation</title><author>Barfield, Raymond Carlton ; Kasow, Kimberly Anne ; Hale, Gregory Alan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-8e2e14846815ea48ddfd0d16322ce1caf42a8095e1d895b11749c33907994c9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Binding</topic><topic>Biology</topic><topic>Bioscience</topic><topic>Calcium</topic><topic>Cancer</topic><topic>Cell</topic><topic>Child</topic><topic>Cycle</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - therapy</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cell Transplantation - trends</topic><topic>Humans</topic><topic>Immunologic Deficiency Syndromes - therapy</topic><topic>Immunotherapy - methods</topic><topic>Landes</topic><topic>Leukemia - therapy</topic><topic>Medical Oncology - methods</topic><topic>Metabolism, Inborn Errors - therapy</topic><topic>Organogenesis</topic><topic>Osteopetrosis - therapy</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barfield, Raymond Carlton</creatorcontrib><creatorcontrib>Kasow, Kimberly Anne</creatorcontrib><creatorcontrib>Hale, Gregory Alan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer biology & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barfield, Raymond Carlton</au><au>Kasow, Kimberly Anne</au><au>Hale, Gregory Alan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in pediatric hematopoietic stem cell transplantation</atitle><jtitle>Cancer biology & therapy</jtitle><addtitle>Cancer Biol Ther</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>7</volume><issue>10</issue><spage>1533</spage><epage>1539</epage><pages>1533-1539</pages><issn>1538-4047</issn><eissn>1555-8576</eissn><abstract>Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) has become a therapeutic option for an increasing number of patients with otherwise incurable leukemias, solid tumors, immunodeficiencies, hemoglobinopathies and metabolic diseases. For patients requiring an allogeneic transplant, the addition of unrelated cord blood units and partially matched family member donors as alternate stem cell sources has increased the chances that an appropriate donor can be identified1,2. In addition, new approaches to stem cell graft engineering are yielding insights into potential cellular immune therapies, which may decrease the adverse effects of HSCT such as graft-versus-host disease (GVHD) and harness the alloimmune graft-versus-leukemia effect. Novel conditioning regimens, primarily reduced intensity and non-myeloablative regimens, allow patients with significant co-morbidities to undergo transplantation with reduced morbidity and mortality. Combinations of immune-modulatory cytokines and monoclonal antibodies with autologous and allogeneic transplantation are among the advances being explored in contemporary HSCT.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>18927494</pmid><doi>10.4161/cbt.7.10.7046</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-4047 |
| ispartof | Cancer biology & therapy, 2008-10, Vol.7 (10), p.1533-1539 |
| issn | 1538-4047 1555-8576 |
| language | eng |
| recordid | cdi_pubmed_primary_18927494 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Binding Biology Bioscience Calcium Cancer Cell Child Cycle Graft vs Host Disease - etiology Graft vs Host Disease - therapy Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - trends Humans Immunologic Deficiency Syndromes - therapy Immunotherapy - methods Landes Leukemia - therapy Medical Oncology - methods Metabolism, Inborn Errors - therapy Organogenesis Osteopetrosis - therapy Proteins |
| title | Advances in pediatric hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A15%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20pediatric%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=Cancer%20biology%20&%20therapy&rft.au=Barfield,%20Raymond%20Carlton&rft.date=2008-10-01&rft.volume=7&rft.issue=10&rft.spage=1533&rft.epage=1539&rft.pages=1533-1539&rft.issn=1538-4047&rft.eissn=1555-8576&rft_id=info:doi/10.4161/cbt.7.10.7046&rft_dat=%3Cproquest_pubme%3E69743441%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69743441&rft_id=info:pmid/18927494&rfr_iscdi=true |